Extracts from
The present invention relates to selected and stabilized cell line extracts from Ajuga reptans comprising phenylpropanoids having high antioxidating capacity with a teupolioside titer of between 20% and 90% and a chromophore-free fraction of between 80% and 10%. Said extracts are for use in human and veterinary therapy and for nutritional and cosmetic purposes. Furthermore, the invention relates to a novel phenylpropanoid molecule denominated isoteupolioside.
1. A pharmaceutical or cosmetic composition comprising:
a physiologically acceptable medium; and
an extract derived in part according to an in-vitro plant cell culture method from an isolated plant cell line of Ajuga reptans IRBN22 (DSM 16451) derived from undifferentiated callus tissues;
wherein the extract comprises a chromophore free fraction and phenylpropanoids comprising isoteupolioside;
the pharmaceutical or cosmetic composition comprising isoteupolioside in a sufficient amount to exhibit a pharmacological or cosmetic activity of at least one of the group selected from an anti-oxidant activity, a platelet aggregation activity, and anti-inflammatory activity, an anti-lipoxygenase activity, an anti-5-alpha-reductase activity, an anti-tyrosinase activity, an anti-fungal activity and a metal-chelating (Fe2+, Fe3+, Cu2+ e Ni2+) activity; and
the isoteupolioside is represented by a general formula (I):
wherein R1 is galactose, R2 is hydrogen, R3 is caffeic acid, R4 is a hydrogen atom and R5 is a hydrogen atom.
2. The pharmaceutical or cosmetic composition according to claim 1 , wherein the extract comprises:
from 20% to 90% by weight phenylpropanoids; and
from 80 to 10% of the chromophore-free fraction comprising oligo- and polysaccharide, protein and lipid molecules.
3. The pharmaceutical or cosmetic composition according to claim 1 , wherein the extract comprises:
between 30% and 60% by weight phenylpropanoids; and
between 70% and 40% of said chromophore-free fraction.
4. The pharmaceutical or cosmetic composition according to claim 2 , wherein the phenylpropanoids comprise between 5% and 25% by weight isoteupolioside with respect to the total mass of phenylpropanoids.
5. The pharmaceutical or cosmetic composition according to claim 2 , wherein the phenylpropanoids comprise between 30% and 65% by weight isoteupolioside with respect to the total mass of phenylpropanoids.
6. A pharmaceutical or cosmetic composition comprising:
an extract having a chromophore-free fraction and phenylpropanoids;
the extract being derived in part from an isolated plant cell line of Ajuga reptans IRBN22 (DSM 16451) and comprising 20% to 80% by weight of phenylpropanoid isomers represented by a general formula (I):
wherein:
R1 is a hydrogen atom or a monosaccharide with 5 or 6 carbon atoms or a disaccharide with 10 to 12 carbon atoms;
R2 is a hydrogen atom or is a caffeoyl (A) group or a feruloyl (B) group;
R3 is a hydrogen atom or a monosaccharide with 5 or 6 carbon atoms or a disaccharide with 10 to 12 carbon atoms or is a caffeoyl (A) group or a feruloyl (B) group;
R4 is a hydrogen atom, or a linear or branched alkyl group with 1 to 3 carbon atoms or a hydroxyl;
R5 is a hydrogen atom, or a linear or branched alkyl group with 1 to 3 carbon atoms wherein;
when R3 is a caffeoyl (A) group or a feruloyl (B) group, then R2 is always a hydrogen atom;
when R2 is a caffeoyl (A) group or a feruloyl (B) group, then R3 is always a hydrogen atom, and
R4 and R5 may be either same or different.
7. The pharmaceutical or cosmetic composition according to claim 1 , wherein the isolated plant cell line is a stabilised cell lines of Ajuga reptans.
8. A formulation comprising plant cell extract as an active ingredient in association with a pharmaceutically or cosmetically acceptable excipient, and the extract being obtained according to a process comprising the following sequence steps:
a) obtaining a biomass of plant cells derived from a selected plant cell line of Ajuga reptans IRBN22 (DSM 16451);
b) facilitating an isomerisation of teupolioside into isoteupolioside having a general formula (I):
by subjecting the biomass to a thermal enzyme deactivating treatment at a temperature of 50-150° C. for 5 to 30 minutes, wherein R1 is galactose, R2 is hydrogen, R3 is caffeic acid; R4 is a hydrogen atom and R5 is a hydrogen atom; then
c) recovering the extract from the biomass and forming the extract to comprise at least 20% by weight of phenylpropanoids, and a chromophore-free fraction facilitating increasing an action of the phenylpropanoids of the extract; and
the phenylpropanoids comprising between 30% and 65% of isoteupolioside with respect to a total mass of the phenylpropanoids.
9. The formulation according to claim 8 wherein the formulation is used for systemic, parenteral, oral, rectal, inhalatory, topical, transdermal, intravenous, intramuscular or subcutaneous administration.
10. The formulation according to claim 9 , wherein the formulation is used for oral administration is represented by tablets, lozenges, capsules, powders, solutions, suspensions or a nebulised form.
11. The formulation according to claim 9 wherein the formulation is used for administration by inhalation is represented by powders, solutions and suspensions.
12. The formulation according to claim 9 , wherein the formulation is used for topical administration is an emulsion, gel or compatible solutions for dermal and mucosal use and eye washes.
13. A nutritional additive derived in part from an extract from a selected plant cell line of Ajura reptans IRBN22 (DSM 16451) derived from selected undifferentiated callus tissues;
facilitating an isomerisation of teupolioside into isoteupolioside having a general formula (I), indicated below, by subjecting a biomass of cells derived from the selected plant cell line to a thermal enzyme deactivating treatment;
the nutritional additive comprising:
a physiologically acceptable medium; and
between 20% and 90% by weight, over the total dry weight of said extract, of phenylpropanoids selected from the group consisting of teupolioside, methylteupolioside, isoteupolioside and mixtures thereof, and the phenylpropanoid isoteupolioside has the general formula (I):
wherein R1 is galactose, R2 is hydrogen, R3 is caffeic acid, R4 is a hydrogen atom and R5 is a hydrogen atom; and
the extract comprises between 80% and 10% by weight, over the total dry weight of the extract, of a chromophore-free fraction.
14. A composition comprising:
a physiologically acceptable medium; and
an extract having a chromophore-free fraction facilitating increasing an action of the extract; and
an isoteupolioside compound of a general formula (I):
wherein R1 is a hydrogen atom or a monosaccharide with 5 or 6 carbon atoms or a disaccharide with 10 to 12 carbon atoms;
R2 is a hydrogen atom or is a caffeoyl (A) group or a feruloyl (B) group;
R3 is a hydrogen atom or a monosaccharide with 5 or 6 carbon atoms or a disaccharide with 10 to 12 carbon atoms or is a caffeoyl (A) group or a feruloyl (B) group;
R4 is a hydrogen atom, or a linear or branched alkyl group with 1 to 3 carbon atoms or a hydroxyl;
R5 is a hydrogen atom, or a linear or branched alkyl group with 1 to 3 carbon atoms;
when R3 is a caffeoyl (A) group or a feruloyl (B) group, then R2 is always a hydrogen atom;
when R2 is a caffeoyl (A) group or a feruloyl (B) group, then R3 is always a hydrogen atom;
R4 and R5 may be either same or different; and
the composition comprises the isoteupolioside compound in sufficient amounts to exhibit a pharmacological or cosmetic activity of at least one of the group selected from a platelet aggregation activity, an anti-oxidating activity, an anti-inflammatory activity, an anti-tyrosinase activity, an anti-lipoxygenase activity, an anti-5-alpha-reductase activity, an anti-fungal activity and a metal-chelating (Fe2+, Fe3+, Cu2+ e Ni2+) activity.